In the hunt for additional NPM1mut peptide targets for future treatment strategies and, ideally, the identification of those that are naturally processed and presented, we could use mass spectrometry technologies that have been previously used to identify LAA-associated peptides processed and presented on MHC on CML and AML cells [107,109]. This evidence concerns the gene HLA-C and chronic myelogenous leukemia, BCR-ABL1 positive.